{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T19:09:32Z","timestamp":1789153772902,"version":"build-2803163510"},"reference-count":25,"publisher":"Society of Nuclear Medicine","issue":"Supplement 2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"accepted":{"date-parts":[[2025,8,20]]},"published-print":{"date-parts":[[2026,9]]},"DOI":"10.2967\/jnumed.125.269486","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T18:40:16Z","timestamp":1789152016000},"page":"30S-35S","source":"Crossref","is-referenced-by-count":0,"title":["Pivotal Phase 3 Theranostic Trials: Future Indications"],"prefix":"10.2967","volume":"67","author":[{"given":"Wolfgang P.","family":"Fendler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Hofman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Kersting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremie","family":"Calais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A.","family":"Hope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2026,9,11]]},"reference":[{"key":"2026091111400904000_67.Supplement_2.30S.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107322"},{"key":"2026091111400904000_67.Supplement_2.30S.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01653-2"},{"key":"2026091111400904000_67.Supplement_2.30S.3","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30860-X"},{"key":"2026091111400904000_67.Supplement_2.30S.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2024.11.027"},{"key":"2026091111400904000_67.Supplement_2.30S.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607427"},{"key":"2026091111400904000_67.Supplement_2.30S.6","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.265077"},{"key":"2026091111400904000_67.Supplement_2.30S.7","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.233460"},{"key":"2026091111400904000_67.Supplement_2.30S.8","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30198-0"},{"key":"2026091111400904000_67.Supplement_2.30S.9","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.236414"},{"key":"2026091111400904000_67.Supplement_2.30S.10","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00529-6"},{"key":"2026091111400904000_67.Supplement_2.30S.11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00237-3"},{"key":"2026091111400904000_67.Supplement_2.30S.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1213755"},{"key":"2026091111400904000_67.Supplement_2.30S.13","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s12672-024-01680-z","article-title":"The therapeutic use of 177Lu-PSMA-617 radioligand therapy in prostate cancer treatment: a review of literature and ongoing trials","volume":"15","author":"Konopnicki","year":"2024","journal-title":"Discov Oncol."},{"key":"2026091111400904000_67.Supplement_2.30S.14","first-page":"e546","article-title":"PSMAddition: phase 3 trial of [177Lu]Lu-PSMA-617 plus standard of care (SoC) vs. Soc alone in patients with metastatic hormone-sensitive prostate cancer [abstract]","volume":"120","author":"Kim","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"2026091111400904000_67.Supplement_2.30S.15","doi-asserted-by":"crossref","first-page":"4132","DOI":"10.1200\/JCO.2023.41.16_suppl.4132","article-title":"ACTION-1 phase Ib\/3 trial of RYZ101 in somatostatin receptor subtype 2\u2013expressing (SSTR2+) gastroenteropancreatic neuroendocrine tumors (GEP-NET) progressing after 177Lu somatostatin analogue (SSA) therapy: initial safety analysis [abstract]","volume":"41","author":"Morris","year":"2023","journal-title":"J Clin Oncol."},{"key":"2026091111400904000_67.Supplement_2.30S.16","doi-asserted-by":"crossref","first-page":"4020","DOI":"10.1200\/JCO.2024.42.16_suppl.4020","article-title":"Safety, tolerability and efficacy of 212Pb-DOTAMTATE as a targeted alpha therapy for subjects with unresectable or metastatic somatostatin receptor-expressing gastroenteropancreatic neuroendocrine tumors (SSTR+ GEP-NETs): a phase 2 study [abstract]","volume":"42","author":"Strosberg","year":"2024","journal-title":"J Clin Oncol."},{"key":"2026091111400904000_67.Supplement_2.30S.17","first-page":"e70018","article-title":"Efficacy and safety of [177Lu]Lu-edotreotide vs. everolimus in patients with grade 1 or grade 2 gastroenteropancreatic neuroendocrine tumours: COMPETE phase 3 trial [abstract]","volume":"37","year":"2025","journal-title":"J Neuroendocrinol."},{"key":"2026091111400904000_67.Supplement_2.30S.18","doi-asserted-by":"crossref","first-page":"S960","DOI":"10.1016\/j.annonc.2022.07.1028","article-title":"902TiP COMPOSE: pivotal phase III trial to compare 177Lu-edotreotide with best standard of care for well-differentiated aggressive grade 2 and grade 3 gastroenteropancreatic neuroendocrine tumours [abstract]","volume":"33","author":"Halfdanarson","year":"2022","journal-title":"Ann Oncol."},{"key":"2026091111400904000_67.Supplement_2.30S.19","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70475-9"},{"key":"2026091111400904000_67.Supplement_2.30S.20","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(25)00009-9"},{"key":"2026091111400904000_67.Supplement_2.30S.21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1510093"},{"key":"2026091111400904000_67.Supplement_2.30S.22","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1016\/S0140-6736(24)00054-0","article-title":"3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial","volume":"403","author":"Perez-Garcia","year":"2024","journal-title":"Lancet."},{"key":"2026091111400904000_67.Supplement_2.30S.23","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1016\/S0140-6736(24)00701-3","article-title":"[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high-dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study","volume":"403","author":"Singh","year":"2024","journal-title":"Lancet."},{"key":"2026091111400904000_67.Supplement_2.30S.24","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30821-6"},{"key":"2026091111400904000_67.Supplement_2.30S.25","doi-asserted-by":"crossref","first-page":"1059122","DOI":"10.3389\/fmed.2022.1059122","article-title":"AlphaBet: combination of radium-223 and [177Lu]Lu-PSMA-I&T in men with metastatic castration-resistant prostate cancer (clinical trial protocol)","volume":"9","author":"Kostos","year":"2022","journal-title":"Front Med (Lausanne)."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.125.269486","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T18:40:30Z","timestamp":1789152030000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.125.269486"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":25,"journal-issue":{"issue":"Supplement 2","published-online":{"date-parts":[[2026,9,11]]},"published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.2967\/jnumed.125.269486"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.125.269486","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]}}}